Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study
…, SL Silverman, FP Alepa, ME Luggen… - Arthritis & …, 1996 - Wiley Online Library
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective
for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory …
for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory …
Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
…, RP Polisson, SR Weiner, ME Luggen… - … : Official Journal of …, 1985 - Wiley Online Library
One hundred eighty‐nine patients with rheumatoid arthritis were entered into a prospective,
controlled, double‐blind multicenter trial comparing placebo and methotrexate (MTX). One …
controlled, double‐blind multicenter trial comparing placebo and methotrexate (MTX). One …
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
Background: Disease-modifying antirheumatic drugs may confer greater benefits when
combined with the antimetabolite methotrexate. Objective: To evaluate the efficacy and safety of …
combined with the antimetabolite methotrexate. Objective: To evaluate the efficacy and safety of …
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis
…, HB Hubert, VB Lingala, JR Elliott, ME Luggen… - Jama, 2007 - jamanetwork.com
ContextHydroxychloroquine, a commonly used antirheumatic medication, has hypoglycemic
effects and may reduce the risk of diabetes mellitus.ObjectiveTo determine the association …
effects and may reduce the risk of diabetes mellitus.ObjectiveTo determine the association …
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study
…, MR Cohen, FB Vasey, ME Luggen… - Arthritis & …, 1996 - Wiley Online Library
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is
effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with …
effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with …
Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared …
…, HE Paulus, LM Billingsley, ME Luggen… - The Journal of …, 1991 - europepmc.org
We identified a cohort of 410 patients with connective tissue disorders (CTD) of less than or
equal to 1 year duration among the participating clinics of the Cooperative Systematic …
equal to 1 year duration among the participating clinics of the Cooperative Systematic …
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase …
…, S Chohan, FJG Fructuoso, ME Luggen… - Annals of the …, 2021 - ard.bmj.com
Objectives To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody
tildrakizumab in patients with psoriatic arthritis (PsA). Methods In this randomised, double-…
tildrakizumab in patients with psoriatic arthritis (PsA). Methods In this randomised, double-…
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and …
…, DO Clegg, CM Ziminski, ME Luggen… - The Journal of …, 1999 - europepmc.org
Objective (1) To review the diagnoses after 10 years in patients who were identified within
12 months of the onset of well established and undifferentiated connective tissue diseases (…
12 months of the onset of well established and undifferentiated connective tissue diseases (…
A population pharmacokinetic‐pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis
…, DC Kwok, MJ Elliott, ME Luggen… - Clinical …, 1999 - Wiley Online Library
Clenoliximab (IDEC‐151) is a macaque‐human chimeric monoclonal antibody (immunoglobulin
G4) specific for the CD4 molecule on the surface of T lymphocytes. It is being studied in …
G4) specific for the CD4 molecule on the surface of T lymphocytes. It is being studied in …
Morbidity from repetitive knee trauma in carpet and floor layers.
…, WE Halperin, ST Lee, ME Luggen… - Occupational and …, 1987 - oem.bmj.com
Carpet layers comprise less than 0.06% of the United States workforce yet they submit 6.2%
of compensation claims for traumatic knee inflammation. Their work involves multiple …
of compensation claims for traumatic knee inflammation. Their work involves multiple …